Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as " bath salts" or " plant food"

Toxicology Letters

Volumn 211, Issue 2, 2012, Pages 144-149

  Coppola, M ^a   Mondola, R ^b  

^a ASL CN2   (Italy)

^b ASL CN1   (Italy)

Author keywords

Bath salts; Designer drug; MDPV; Mephedrone; Synthetic cathinone

Indexed keywords

CATHINONE; DESIGNER DRUG; RECREATIONAL DRUG;

CHEMICAL ANALYSIS; DRUG DEPENDENCE; DRUG USE; FATALITY; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; WITHDRAWAL SYNDROME;

ALKALOIDS; DESIGNER DRUGS; HUMANS; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

MUSCOVY DUCK PARVOVIRUS;

EID: 84859628524     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.03.009     Document Type: Review

References (62)

1. Al-Halbori M. The potential adverse effects of habitual use of Catha edulis (khat). Expert. Opin. Drug Saf. 2005, 4:1145-1154.
2. Balint E.E., Falkay G., Balint G.A. Khat-a controversial plant. Wien. Klin. Wochenschr. 2009, 121:604-614.
3. Baron D.N. A memorable experience: the qat party. BMJ 1999, 319:500.
4. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of bath salts containing 3,4-methylenedioxypyrovalerone. Ann. Emerg. Med. 2012, 10.1016/j.annemergmed.2012.01.005.
5. Brandt S.D., Freeman S., Summale H.R., Measham F., Cole J. Analysis of NRG Legal highs in the UK: identification and formation of novel cathinones. Drug Test. Anal. 2010, 2:377-382.
6. Brenneisen R., Fisch H.V., Koelbing V., Geisshusler S., Kalix P. Amphetamine-like effect in humans of the khat alkaloid cathinone. Br. J. Clin. Pharmacol. 1990, 30:825-828.
7. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend. 2011, 118:19-22.
8. Carroli F.I., Blough B.E., Abraham P., Mills A.C., Holleman J.A., Wolckenhauer S.A., et al. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 2009, 52:6768-6781.
9. Carter N., Rutty G.N., Milroy C.M., Forrest A.R. Deaths associated with MBDB misuse. Int. J. Legal Med. 2000, 113:168-170.
10. Centers for Control and Prevention (CDC) Emergency visits after use of a drug sold as " bath salts" -Michigan, November 13, 2010-March 31, 2011. MMWR Morb. Mortal. Wkly. Rep. 2011, 60:624-627.
11. Colzato L.S., Ruiz M.J., Van den Wildenberg W.P.M., Hommel B. Khat use is associated with impaired working memory and cognitive flexibility. PLoS One 2011, 6:e20602.
12. Coppola M., Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol. Lett. 2012, 5:12-15.
13. Cozzi N.V., Sievert M.K., Shulgin A.T., Jaco P., Ruoho A.E. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol. 1999, 381:63-69.
14. Dargan P.I., Albert S., Wood D.M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-879.
15. Dargan P.I., Sedefov R., Gallegos A., Wood D.M. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug. Test. Anal. 2011, 3:454-463.
16. Davies S., Wood D.M., Smith G., Button J., Ramsey J., Archer R., et al. Purchasing legal highs on the Internet-is there consistency in what you get?. QJM 2010, 103:489-493.
17. Durham M. Ivory wave: the next mephedrone?. Emerg. Med. J. 2011, 28:1059-1060.
18. Foltin R.W., Schuster C.R. Behavioral tolerance and cross-tolerance to dl-cathinone and d-amphetamine in rats. J. Pharmacol. Exp. Ther. 1982, 222:126-131.
19. Gibbons S., Zloh M. An analysis of legal high mephedrone. Bioorg. Med. Chem. Lett. 2010, 20:4135-4139.
20. Griffiths P., Gossop M., Wickenden S., Dunworth J., Harris K., Lloyd C.A. A transcultural patterned drug use: qat (khat), in the UK. Br. J. Psychiatry 1997, 170:281-284.
21. Gustavsson D., Escher C. Mephedrone-internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substances. Lakartidningen 2009, 106:2769-2777.
22. Gygi M.P., Fleckenstein A.E., Gibb J.W., Hanson G.R. Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J. Pharmacol. Exp. Ther. 1996, 283:1350-1355.
23. Halbach H. Medical aspects of the chewing of khat leaves. Bull. World Health Organ. 1972, 47:21-29.
24. Hassan N.A., Gunaid A.A., Murray-Lyon I.M. Khat (Catha edulis): health aspects of khat chewing. East Mediterr. Health J. 2007, 13:706-718.
25. James D., Adams R.D., Spears R., Cooper G., Lupton D.J., Thompson J.P., et al. Clinical characteristics of mephedrone toxicity reported to the UK Poison Information Service. Emerg. Med. J. 2011, 28:686-689.
26. Kalix P. The releasing effect of the isomers of the alkaloid cathinone at central and peripheral catecholamine storage sites. Neuropharmacology 1986, 25:499-501.
27. Kalix P. Pharmacological properties of the stimulant khat. Pharmacol. Ther. 1990, 48:397-416.
28. Kalix P. Cathinone: a natural amphetamine. Pharmacol. Toxicol. 1992, 70:77-86.
29. Kalix P. Catha edulis, a plant that has amphetamine effects. Pharm. World Sci. 1996, 18:69-73.
30. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test. Anal. 2011, 9:552-559.
31. Karila L., Weinstein A., Aubin H.J., Benyamina A., Reynaud M., Batki S.L. Pharmacological approaches to methamphetamine dependence: a focused review. Br. J. Clin. Pharmacol. 2010, 69:578-592.
32. Kelly J.P. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test. Anal. 2011, 3:439-453.
33. Kikura-Hanajiri R., Kawamura M., Saisho K., Kodama Y., Goda Y. The disposition into hair of new designer drugs: methylone, MBDB and methcathinone. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 855:121-126.
34. Kriikku P., Wilhelm L., Schwarz O., Rintatalo J. New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci. Int. 2011, 210:195-200.
35. Maskell P.D., De Paoli G., Seneviratne C., Pounder D.J. Mephedrone (4-methylmethcathinone)-related deaths. J. Anal. Toxicol. 2001, 35:188-191.
36. McNamara S., Stokes S., Coleman N. Head shop compound abuse amongst attendees of the Drug Treatment Centre Board. Intern. Med. J. 2010, 103:134-137.
37. Measham F., Moore K., Newcombe R., Welch Z. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perverity of prohibition. Drug Alcohol Today 2010, 10:14-21.
38. Meltzer P.C., Butler D., Deschamps R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49:1420-1432.
39. Meyer M.R., Maurer H.H. Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 2010, 11:468-482.
40. Meyer M.R., Wilhelm J., Peters J., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone, and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2010, 397:1225-1233.
41. Mugele J., Nanagas K.A., Tormoehlen L.M. Serotonin syndrome associated with MDPV use: a case report. Ann. Emerg. Med. 2012, http://dx.doi.org/10.1016/j.annemergmed.2011.11.033.
42. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug Bath salts containing 3,4-Methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 10.1007/s13181-011-0196-9.
43. Nencini P., Amiconi G., Befani O., Abdullahi M.A., Anania M.C. Possible involvement of amine oxidase inhibition in the sympathetic activation by khat (Catha edulis) chewing in humans. J. Ethnopharmacol. 1984, 11:78-86.
44. Ojanpera I.A., Heikman P.K., Rasanen I.J. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther. Drug Monit. 2011, 33:257-263.
45. Panders T.M., Gestring R. Hallucinatory delirium following use of MDPV: bath salts. Gen. Hosp. Psychiatry 2011, 33:525-526.
46. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 2012, 8:33-42.
47. Rau K.S., Birdsall E., Hanson J.E., Johnson-Davis K.L., Carrol F.I., Wilkins D.J., et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 2005, 49:820-830.
48. Regan L., Mitchelson M., Macdonald C. Mephedrone toxicity in Scottish emergency department. Emerg. Med. J. 2011, 28:1055-1058.
49. Ross S., Peselow E. The neurobiology of addictive disorders. Clin. Neuropharmacol. 2009, 32:269-276.
50. Schechter M.D. Dopaminergic nature of acute cathine tolerance. Pharmacol. Biochem. Behav. 1990, 36:817-820.
51. Schifano F., Ricciardi A., Corazza O., Deluca P., Davey Z., Rafanelli C., et al. New drugs of abuse on the web: the role of the Psychonaut Web Mapping Project. Riv. Psichiatr. 2010, 45:88-93.
52. Schorno X., Steinegger E. CNS-active phenylpropylamines of Chata edulis Forsk (Celastraceae) of Kenyan origin. Experientia 1979, 35:572-574.
53. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of bath salts and legal highs(synthetic cathinones) in the United States. Clin. Toxicol. (Phila.) 2011, 49:499-505.
54. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botrè F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass-spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 24:2706-2714.
55. Torrance H., Cooper G. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci. Int. 2010, 202:e62-e63.
56. Walsh C. Drugs, the internet and change. J. Psychoactive Drugs 2011, 43:55-63.
57. Wikstrom M., Thelander G., Nystrom I., Kronstrand R. Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J. Anal. Toxicol. 2010, 34:594-598.
58. Winstock A.R., Mitcheson L.R., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376:1537.
59. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
60. Wood D.M., Davies S., Puchnarewicz M., Button J., Archer R., Ovaska H., et al. Recreational use of mephedrone (4-methylmethcathinone) with associated sympathomimetic toxicity. J. Med. Toxicol. 2010, 6:327-330.
61. Yousef G., Huq Z., Lambert T. Khat chewing as a cause of psychosis. Br. J. Hosp. Med. (Lond.) 1995, 54:322-326.
62. Zaitus K., Katagi M., Kamata H.T., Kamata T., Shima N., Miki A., et al. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci. Int. 2009, 188:131-139.